Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT00253617
Other study ID # AXCAN-PHOCCC04-01
Secondary ID UCLA-0501033-01C
Status Withdrawn
Phase Phase 3
First received November 11, 2005
Last updated April 2, 2013

Study information

Verified date December 2006
Source National Cancer Institute (NCI)
Contact n/a
Is FDA regulated No
Health authority United States: Federal Government
Study type Interventional

Clinical Trial Summary

RATIONALE: Stent placement may help reduce symptoms caused by the tumor. Photodynamic therapy uses a drug, such as porfimer sodium, that becomes active when it is exposed to a certain kind of light. When the drug is active, tumor cells are killed. This may be an effective treatment for cholangiocarcinoma. It is not yet known whether stent placement and photodynamic therapy using porfimer sodium are more effective than stent placement alone in treating cholangiocarcinoma.

PURPOSE: This randomized phase III trial is studying stent placement and photodynamic therapy using porfimer sodium to see how well they work compared to stent placement alone as palliative treatment in treating patients with stage III or stage IV cholangiocarcinoma that cannot be removed by surgery.


Description:

OBJECTIVES:

Primary

- Compare the overall survival time in patients with unresectable Bismuth type III or IV, stage III-IV cholangiocarcinoma treated with double plastic endoprostheses insertion with vs without adjuvant photodynamic therapy using porfimer sodium as palliative treatment.

Secondary

- Compare the effect of these regimens on cholestasis in these patients.

- Compare the 1-year survival rate in patients treated with these regimens.

- Compare health-related quality of life of patients treated with these regimens.

OUTLINE: This is a randomized, controlled, open-label, multicenter study. Patients are stratified according to participating center.

Patients undergo endoscopic or percutaneous drainage followed by insertion of bilateral plastic endoprostheses into the bile ducts. Patients are then randomized to 1 of 2 treatment arms.

- Arm I: Patients receive porfimer sodium IV on day 1. Patients undergo endoscopic laser light therapy to the tumor site on day 3.

- Arm II: Patients receive no further treatment. Quality of life is assessed at baseline and then at weeks 2, 13, 26, 39, 52, and 65.

After completion of study treatment, patients are followed within 30-90 days.

PROJECTED ACCRUAL: A total of 120 patients (60 per treatment arm) will be accrued for this study.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility DISEASE CHARACTERISTICS:

- Histologically or cytologically confirmed cholangiocarcinoma

- Stage III or IV disease

- Bismuth type III or IV disease

- Tumor mass or stricture on cholangiogram and CT scan

- Unresectable disease

PATIENT CHARACTERISTICS:

Performance status

- Karnofsky 30-100%

Life expectancy

- Not specified

Hematopoietic

- WBC = 2,000/mm^3

- Platelet count = 50,000/mm^3

- Hemoglobin = 9.0 g/dL

- Hematocrit = 27%

Hepatic

- PT or INR = 2 times upper limit of normal (correctable with vitamin K)

- No decompensated cirrhosis

Renal

- Not specified

Other

- Not pregnant

- Negative pregnancy test

- Fertile patients must use effective contraception

- No known porphyria or hypersensitivity to porphyrin

- No clinically significant acute or chronic medial or psychological illness that would preclude study treatment

- No other malignancy within the past 5 years except carcinoma in situ of the cervix or basal cell skin cancer

- No concurrent untreated primary diagnosis of anxiety or depression

PRIOR CONCURRENT THERAPY:

Chemotherapy

- More than 13 weeks since prior and no concurrent chemotherapy

Radiotherapy

- More than 13 weeks since prior and no concurrent brachytherapy or radiotherapy

Surgery

- No prior metal stent insertion

- No prior surgical resection of cholangiocarcinoma

Other

- No prior photodynamic therapy for this disease

- More than 60 days since prior investigational drugs

- No concurrent administration of the following:

- Ursodiol

- Herbal products that may increase bile flow, including any of the following:

- Andrographis paniculata

- Chelidonium majus L

- Curcumin L

- Cynara scolymus L (artichoke)

- Gentiana lutea

- Mentha x piperita (peppermint)

- Peumus boldus Mol

- Taraxacum officinale (dandelion)

- No administration of any of the following within 7 days of porfimer sodium injection:

- Supplements in vitamins C, E, and ß-carotene

- Camellia sinensis (green tea)

- Silymarin

- EGb761

Study Design

Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
porfimer sodium

Procedure:
adjuvant therapy

laser therapy

photodynamic therapy

phototherapy


Locations

Country Name City State
Canada Axcan Pharma, Incorporated Mont-Saint-Hilaire Quebec
United States Jonsson Comprehensive Cancer Center at UCLA Los Angeles California

Sponsors (2)

Lead Sponsor Collaborator
Jonsson Comprehensive Cancer Center National Cancer Institute (NCI)

Countries where clinical trial is conducted

United States,  Canada, 

See also
  Status Clinical Trial Phase
Completed NCT01229111 - Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers Phase 2
Completed NCT00238212 - S0514 Sorafenib in Treating Patients With Unresectable or Metastatic Gallbladder Cancer or Cholangiocarcinoma Phase 2
Completed NCT00107536 - Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer Phase 2
Active, not recruiting NCT00553332 - Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery Phase 2
Completed NCT00101036 - Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery Phase 2
Completed NCT01766219 - CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery Phase 1/Phase 2
Terminated NCT00478140 - Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery Phase 2
Completed NCT00356889 - Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic or Unresectable Biliary Tumors Phase 2
Terminated NCT00087191 - EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer N/A
Completed NCT01643499 - Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies Phase 1
Completed NCT00033462 - Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer Phase 2
Withdrawn NCT01859182 - Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery Phase 2
Terminated NCT01282333 - Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung Cancer Phase 1
Completed NCT00397384 - Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer Phase 1
Completed NCT00085410 - Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder Phase 2
Completed NCT00031681 - 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) Phase 1
Terminated NCT00023946 - BMS-247550 in Treating Patients With Liver or Gallbladder Cancer Phase 2
Completed NCT00004074 - Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Phase 1